Clinical trialNCT02608099CompletedPhase 4Interventional

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

SponsorBaim Institute for Clinical ResearchEnrollment300Atrial Fibrillation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF). Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Christopher P Cannon, MD
Harvard Clinical Research Organization and Cardiovascular Division Brigham and Women's Hospital
Principal Investigator
clinicaltrials.gov ↗
Matthew Reynolds, MD, MSc
Lahey Hospital & Medical Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Site 0020
Huntsville, Alabama, United States
Site 0005
Mission Viejo, California, United States
Site 0012
New Haven, Connecticut, United States
Site 0011
Trumbull, Connecticut, United States
Site 0016
Pensacola, Florida, United States
Site 0014
West Des Moines, Iowa, United States
Site 0018
Bangor, Maine, United States
Site 0004
Scarborough, Maine, United States
Site 0008
Boston, Massachusetts, United States
Site 0001
Burlington, Massachusetts, United States
Site 0006
Kansas City, Missouri, United States
Site 0021
Omaha, Nebraska, United States
Site 0019
Albuquerque, New Mexico, United States
Site 0002
Toledo, Ohio, United States
Site 0007
Oklahoma City, Oklahoma, United States
Site 0009
Philadelphia, Pennsylvania, United States
Site 0010
Charleston, South Carolina, United States
Site 0017
Austin, Texas, United States
Site 0003
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Interrupted apixabanUninterrupted apixaban

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2015
Primary completion: 30 Apr 2017
Completion: 30 Apr 2017
Last update posted: 17 Mar 2020
Registered enrollment: 300
Registry id: NCT02608099

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.